Status:

COMPLETED

Impact of Changing the Dosing Regimen on the PK Profile of ODM-203

Lead Sponsor:

Orion Corporation, Orion Pharma

Collaborating Sponsors:

Quotient Clinical

Conditions:

Healthy

Eligibility:

MALE

18-55 years

Phase:

PHASE1

Brief Summary

This Phase I study in healthy male volunteers will evaluate the impact of the effect of food on the pharmacokinetic profile of ODM-203.

Detailed Description

This study will be a single dose part randomised cross over study with up to 6 study periods. ODM-203 may be dosed using a variety of different conditions with respect to food depending on emerging da...

Eligibility Criteria

Inclusion

  • Written informed consent
  • Able to speak, write and understand English
  • Body mass index of 18.0-32.0
  • Weight 55-95 kg
  • Adequate method of contraception
  • Good state of health

Exclusion

  • Receipt of IMP in a clinical research study or donation/loss of \>400ml blood within previous 3 months or previously enrolled in this study
  • History of drug or alcohol abuse or positive drugs of abuse test or regular alcohol consumption or current smoker/user of nicotine replacement products
  • Positive drugs of abuse test
  • Positive hepatitis B, hepatitis C or HIV results
  • Donation/loss of \>400ml blood within previous 3 months
  • Poor compliance or inability to follow protocol requirements/instructions/restrictions.
  • Vulnerable subjects
  • Evidence of clinically relevant disease of any body system including relevant psychiatric disorders or conditions requiring regular concomitant medication
  • History of significant hypersensitivity, anaphylaxis, intolerance to drugs/food
  • Propensity to get headaches when refraining from caffeine containing beverages
  • Any abnormal laboratory value, vital signs, ECG parameter or physical examination interfering with the test results or causing a health risk for the subject or failure to satisfy the investigator of fitness to participate for any other reason.

Key Trial Info

Start Date :

August 24 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 23 2017

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT03240445

Start Date

August 24 2017

End Date

October 23 2017

Last Update

May 14 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Quotient Clinical Ltd

Nottingham, United Kingdom, NG11 6JS

Impact of Changing the Dosing Regimen on the PK Profile of ODM-203 | DecenTrialz